Subscribe to RSS
DOI: 10.1055/a-1589-7520
S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL
Wesentliche Neuerungen in der Leitlinie zur Diagnostik und Therapie des hepatozellulären Karzinoms
Die S3-Leitlinie „Diagnostik und Therapie des hepatozellulären Karzinoms und der biliären Karzinome“ umfasst 2 Tumorentitäten. Bisher besteht nur eine Leitlinie zur Diagnostik und Therapie des hepatozellulären Karzinoms (HCC). Daher wird in diesem Kapitel nur auf die Veränderungen der Leitlinie des hepatozellulären Karzinoms eingegangen.
Folgende wesentliche Änderungen ergeben sich zur S3-Leitlinie des hepatozellulären Karzinoms von 2013:
-
Histopathologische und molekulare Diagnostik (S. 94): Die Leberbiopsie wurde als wichtige diagnostische Maßnahme zur Diagnosestellung des hepatozellulären Karzinoms (in der zirrhotischen Leber) gestärkt. In der palliativen Situation sollte eine bioptische Sicherung erfolgen.
-
Bildgebende Diagnostik (S. 94): Bisher wurde in einer zirrhotischen Leber die Diagnose eines hepatozellulären Karzinoms ab 2 cm mittels zweier unabhängiger Bildgebungen (MRT, CT oder Ultraschall) bei typischem Kontrastverhalten gestellt. Die Empfehlung wurde dahingehend geändert, dass die Diagnose eines hepatozellulären Karzinoms in zirrhotischer Leber aufgrund eines typischen Kontrastmittelverhaltens mit arterieller Hypervaskularisation und Auswaschen in der portalvenösen und venösen Phase im kontrastverstärkten MRT diagnostiziert werden soll. Bei unklarem MRT-Befund sollten ein triphasisches CT und/oder ein kontrastverstärkter Ultraschall herangezogen werden.
-
Chirurgische Therapieverfahren (S. 96): Bei geeigneten Patienten mit einem HCC außerhalb der Mailand-Kriterien und innerhalb der UCSF-Kriterien kann eine Lebertransplantation erfolgen, insbesondere dann, wenn ein Downstaging bis innerhalb der Mailand-Kriterien gelingt. Zum Downstaging stehen, ebenso wie beim Bridging, mehrere Therapieverfahren (transarterielle Verfahren, ablative Verfahren und Leberresektion) zur Verfügung.
-
Interventionelle Therapieverfahren (S. 96):
-
Als Standardmethode der lokalablativen Verfahren war bisher nur die Radiofrequenzablation empfohlen. Aufgrund der inzwischen guten Datenlage für die Mikrowellenablation wurde diese als äquivalentes Verfahren aufgenommen.
-
Die transarterielle Chemoembolisation (TACE) sollte mehrfach durchgeführt werden, solange ein Ansprechen hierauf nachweisbar ist und behandelbare hypervaskularisierte Tumoranteile verbleiben.
-
Die Indikation zur Fortführung der TACE soll nach 2 Behandlungszyklen im Tumorboard überprüft werden.
-
Die transarterielle Radioembolisation (TARE) kann nach Beschluss des Tumorboards bei Patienten mit erhaltener Leberfunktion im intermediären HCC-Stadium anstelle einer TACE eingesetzt werden.
-
Eine Hochpräzisionsradiotherapie (Stereotactic Body Radiotherapy, SBRT) kann in Betracht gezogen werden, wenn andere lokale Therapieverfahren nicht möglich sind (z. B. hohe Wahrscheinlichkeit für ein Therapieversagen, eingeschränkte Leberfunktion, technische Hindernisse).
-
-
Systemtherapie (S. 101): Zum Zeitpunkt der letzten Leitlinie konnte nur Sorafenib evidenzbasiert empfohlen werden. Zwischenzeitlich sind mehrere weitere Substanzen hinzugekommen:
-
Die Kombinationstherapie von Atezolizumab und Bevacizumab ist als Erstlinie zugelassen und in der Zulassungsstudie Sorafenib überlegen.
-
Als weitere Erstlinientherapie ist der Tyrosinkinase-Inhibitor Lenvatinib zugelassen.
-
Mehrere Tyrosinkinase-Inhibitoren und der VEGFR-R2-Antikörper Ramucirumab (bei AFP > 400 ng/ml) stehen als weitere zugelassene Therapieoptionen zur Verfügung.
-
Publication History
Article published online:
18 January 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Howick J. et al The 2011 Oxford CEBM Evidence Levels of Evidence (Introductory Document). Available from: http://www.cebm.net/index.aspx?o=5653_2011
- 2 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – Ständige Kommission, L. AWMF-Regelwerk „Leitlinien“. 1. Auflage 2012 [cited 09.12.2013]. Available from: http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk.html
- 3 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
- 4 Brouwer WP. et al. Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. J Viral Hepat 2017; 24: 1023-1031
- 5 Papatheodoridis G. et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016; 64: 800-806
- 6 EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236
- 7 Inoue M. et al. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97 (04) 293-300
- 8 Bravi F. et al. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev 2017; 26: 368-377
- 9 Aleksandrova K. et al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2015; 102: 1498-1508
- 10 Setiawan VW. et al Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015; 148: 118-125 ; quiz e15
- 11 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422
- 12 Pocha C. et al. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography – a randomised study. Aliment Pharmacol Ther 2013; 38: 303-312
- 13 Trinchet JC. et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987-1997
- 14 Tzartzeva K. et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718.e1
- 15 Song BG. et al. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. Eur J Gastroenterol Hepatol 2018; 30: 1447-1452
- 16 Ioannou GN. et al. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology 2019; 157: 1264-1278.e4
- 17 Burrel M. et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38: 1034-1042
- 18 Di Martino M. et al. Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol 2013; 23: 887-896
- 19 Haradome H. et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 2011; 34: 69-78
- 20 Khalili K. et al. Optimization of imaging diagnosis of 1–2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011; 54: 723-728
- 21 Chan AC. et al. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford) 2013; 15: 439-448
- 22 Chevret S. et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe dʼEtude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 133-141
- 23 Johnson PJ. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33: 550-558
- 24 Kitai S. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 2008; 75 (Suppl. 01) 83-90
- 25 Leung TW. et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94: 1760-1769
- 26 Marrero JA. et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-716
- 27 Pinato DJ. et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol 2017; 66: 338-346
- 28 Vitale A. et al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc 2009; 41: 1260-1263
- 29 Yau T. et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-1700.e3
- 30 Huang X, Lu S. Impact of preoperative locoregional therapy on recurrence and patient survival following liver transplantation for hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol 2017; 52: 143-149
- 31 Kulik L. et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology 2018; 67: 381-400
- 32 Sneiders D. et al. Systematic Review and Meta-Analysis of Posttransplant Hepatic Artery and Biliary Complications in Patients Treated With Transarterial Chemoembolization Before Liver Transplantation. Transplantation 2018; 102: 88-96
- 33 Degroote H. et al. Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium. Surg Oncol 2019; 33: 231-238
- 34 Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl 2015; 21: 1142-1152
- 35 Bruix J. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16: 1344-1354
- 36 Lee JH. et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148: 1383-1391.e6
- 37 Mazzaferro V. et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554
- 38 Samuel M. et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009; 1: Cd001199
- 39 Takayama T. et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-807
- 40 Chen MS. et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328
- 41 Feng K. et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57: 794-802
- 42 Huang J. et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252: 903-912
- 43 Ng KKC. et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 2017; 104: 1775-1784
- 44 Yin L. et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol 2014; 61: 82-88
- 45 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60
- 46 Di Costanzo GG. et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol 2015; 30: 559-565
- 47 Cucchetti A. et al. An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Dig Liver Dis 2014; 46: 257-263
- 48 Peng ZW. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31: 426-432
- 49 Liu H. et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg 2016; 103: 348-356
- 50 Endo K. et al. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Scand J Gastroenterol 2018; 53: 1575-1583
- 51 Lo CM. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171
- 52 Llovet JM. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
- 53 Golfieri R. et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255-264
- 54 Lammer J. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52
- 55 Abdel-Rahman O, Elsaye Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020; 1: Cd011313
- 56 Yang Y, Si T. Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Biol Med 2018; 15: 299-310
- 57 Ludwig JM. et al. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus (90)Y-radioembolization for hepatocellular carcinoma. Eur Radiol 2017; 27: 2031-2041
- 58 Casadei Gardini A. et al. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther 2018; 11: 7315-7321
- 59 Finn RS. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905
- 60 Cheng AL. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34
- 61 Llovet JM. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
- 62 Kudo M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet 2018; 391: 1163-1173
- 63 Bruix J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56-66
- 64 Abou-Alfa GK. et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018; 379: 54-63
- 65 Zhu AX. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 282-296
- 66 Marrero JA. et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol 2016; 65: 1140-1147
- 67 Ganten TM. et al. Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study. Clin Cancer Res 2017; 23: 5720-5728
- 68 Leal CRG. et al. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Invest New Drugs 2018; 36: 911-918
- 69 Pressiani T. et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013; 24: 406-411
- 70 Ogasawara S. et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015; 33: 729-739
- 71 Vilgrain V. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18: 1624-1636
- 72 Lencioni R. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016; 64: 1090-1098
- 73 Meyer T. et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2: 565-575
- 74 Chow PKH. et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018; 36: 1913-1921